Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807498 | 0.87 | CA1 (0.47) | CA1CA2BCHEACHEALDH1A1 | |
| SCHEMBL1809484 | 0.86 | NPC1 (0.50) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL1809936 | 0.86 | CA1 (0.40) | CA1CA2ALDH1A1CYP3A4TSHR | |
| SCHEMBL1809147 | 0.85 | HPGD (0.42) | ALDH1A1MAPK1TSHRMAPTKMT2A | |
| SCHEMBL3971351 | 0.84 | BTN3A1 (0.41) | L3MBTL1LMNA | |
| SCHEMBL873273 | 0.84 | BTN3A1 (0.41) | L3MBTL1LMNA | |
| SCHEMBL1808429 | 0.82 | ALDH1A1 (0.37) | ALDH1A1MAPTNPC1RAB9APOLB | |
| SCHEMBL12621313 | 0.77 | CA1 (0.50) | CA1CA2BCHEACHEALDH1A1 | |
| SCHEMBL3970116 | 0.76 | TSHR (0.39) | TSHRL3MBTL1RECQL | |
| SCHEMBL3970115 | 0.76 | TSHR (0.39) | TSHRL3MBTL1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904365-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2022-09-07 | — | — | EP | disclosed |
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3040340-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-11-14 | — | — | EP | disclosed |
| EP-3031812-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-08-01 | — | — | EP | disclosed |
| US-10022390-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2018-07-17 | — | — | US | disclosed |
| EP-2955190-B1 | Chemical compounds | NuCana plc (GB) | 2018-03-28 | — | — | EP | disclosed |
| EP-1646639-B1 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | NUCANA BIOMED LTD (GB) | 2016-08-17 | — | — | EP | disclosed |
| EP-3040340-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-07-06 | — | — | EP | disclosed |
| US-9221866-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NUCANA BIOMED LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| EP-2955190-A2 | Chemical compounds | NuCana BioMed Limited (GB) | 2015-12-16 | — | — | EP | disclosed |
| US-20150183817-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2015-07-02 | — | — | US | disclosed |
| US-8933053-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NUCANA BIOMED LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20140057866-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2014-02-27 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022390-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | CA1 4690/4885CA2 4213/4885BCHE 3099/4885 |
| US-20140057866-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | CA1 4716/4885CA2 4201/4885BCHE 3104/4885 |
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | CA1 3410/4885CA2 3388/4885BCHE 762/4885 |
| US-20150183817-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | CA1 4693/4885CA2 4170/4885BCHE 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.